In vitro

The World Market for Molecular Diagnostics, 2019 to 2024 - Analysis on CT/NG, HPV, Hepatitis, HIV, HAIs, Respiratory Diseases, and Tuberculosis

Retrieved on: 
Wednesday, September 18, 2019
Medical tests, Medicine, Biotechnology, Molecular diagnostics, Biology, Life sciences, Laboratory techniques, In vitro, IVD, Qiagen, Innogenetics

Dublin, Sept. 18, 2019 (GLOBE NEWSWIRE) -- The "The World Molecular Diagnostics Market, 8th Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Sept. 18, 2019 (GLOBE NEWSWIRE) -- The "The World Molecular Diagnostics Market, 8th Edition" report has been added to ResearchAndMarkets.com's offering.
  • Molecular diagnostics is a fast evolving and dynamic field and is the fastest growing segment within the in vitro diagnostics (IVD) market.
  • Clinical molecular tests available for infectious disease testing offer a combination of high sensitivity, specificity and low turnaround time advantages.
  • World Molecular Diagnostics Market covers the markets for molecular blood screening diagnostics, outlining the blood testing market by geography.

The in-vitro toxicity testing market is expected to record a CAGR of almost 7% during 2019-2023

Retrieved on: 
Monday, September 16, 2019
Toxicology, Alternatives to animal testing, Health, Pharmacology, Laboratory techniques, Articles, Tests, In vitro, Toxicity, Toxicology testing, Pharmaceutical industry, In vitro toxicology

Global In-Vitro Toxicity Testing Market: About this Market

Key Points: 
  • Global In-Vitro Toxicity Testing Market: About this Market
    In-vitro toxicity testing is designed to identify toxic components in biological samples.
  • This in-vitro toxicity testing market analysis considers sales to the pharmaceutical and biotechnology companies, academic and research institutions, and others.
  • Also, our global in-vitro toxicity testing report has observed market growth factors such as increasing use of in-vitro toxicity testing by companies to reduce drug failures, presence of toxic substances, and rising number of awareness programs.
  • Consequently, the in-vitro toxicity testing market is expected to record a CAGR of almost 7% during 2019-2023.

Global In-Vitro Diagnostics Market Forecast to 2022 with Profiles of Siemens Healthineers, F. Hoffmann-La Roche, Danaher, Abbott Laboratories, Thermo Fisher Scientific - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 11, 2019
Health, Biotechnology, Medical device, In vitro

Global In-Vitro Diagnostics Market Forecast to 2022 provides strategists, marketers and senior management with the critical information they need to assess the global in-vitro diagnostics market.

Key Points: 
  • Global In-Vitro Diagnostics Market Forecast to 2022 provides strategists, marketers and senior management with the critical information they need to assess the global in-vitro diagnostics market.
  • The in-vitro diagnostics devices (or) equipment manufacturing market consists of sales of in-vitro diagnostic equipment and related services by entities (organizations, sole traders and partnerships) that produce in-vitro diagnostics.
  • North America was the largest region in the global in-vitro diagnostics market, accounting for 35% of the market in 2018.
  • Asia Pacific was the second largest region accounting for 34% of the global in-vitro diagnostics market.

China In-Vitro Diagnostics Market 2019-2023 - Growth Opportunities, Regulatory Developments, Strategic Imperatives

Retrieved on: 
Tuesday, September 10, 2019
IVD, Marketplace, In vitro

DUBLIN, Sept. 10, 2019 /PRNewswire/ -- The "Chinese In-Vitro Diagnostics Market Insight, Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 10, 2019 /PRNewswire/ -- The "Chinese In-Vitro Diagnostics Market Insight, Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
  • The In-vitro Diagnostics (IVD) market in China shows strong growth potential in several segments.
  • On the supply side, foreign companies are dominating the high-end market by leveraging their technical advantage to develop closed-end systems for their automatic analyzers.
  • The IVD market in China presents a diversified growth potential for the different tiers of competitors: domestic participants gain from the growth momentum for the low-end market, whereas leading foreign manufacturers dominate the high-end market, which is expected to become the new emerging market along with ever-improving localized services to meet various demands.

Global In-vitro Toxicity Testing Market 2019-2023 | 7% CAGR Projection Over the Next Five Years | Technavio

Retrieved on: 
Tuesday, September 10, 2019
Veterinary, Research, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Alternatives to animal testing, Toxicology, Laboratory techniques, In vitro, Toxicity, Natural sciences, Health

View the full release here: https://www.businesswire.com/news/home/20190910005665/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190910005665/en/
    Technavio has published a new market research report on the global in-vitro toxicity testing market from 2019-2023.
  • Request Free Sample Pages
    The market is driven by the increasing use of in-vitro toxicity testing by companies to reduce drug failures.
  • In addition, the rising number of awareness programs is anticipated to further boost the In-vitro toxicity testing market during the forecast period.
  • Thus, the use of in-vitro toxicity testing to reduce drug failures will drive market growth during the forecast period.

Specific Diagnostics Announces That Eric B. Stang Joins Its Advisory Board

Retrieved on: 
Monday, September 9, 2019
Rambus, Ooma, In vitro, Stang, Companies, California, Economy of the United States

MOUNTAIN VIEW, Calif., Sept. 9, 2019 /PRNewswire-PRWeb/ -- Specific Diagnostics is very pleased to announce that Eric B. Stang has joined Specific's Advisory Board.

Key Points: 
  • MOUNTAIN VIEW, Calif., Sept. 9, 2019 /PRNewswire-PRWeb/ -- Specific Diagnostics is very pleased to announce that Eric B. Stang has joined Specific's Advisory Board.
  • Mr. Stang is an experienced public company CEO and Board Member, currently CEO and Chairman of OOMA (NYSE), as well as member of the Board of Directors of Rambus (NASDAQ).
  • Specific has developed in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture.
  • Specific Diagnostics is located in two buildings in Mountain View, CA, with an office in Cambridge, UK.

Chris Smith Named Next Chief Executive Officer of Ortho Clinical Diagnostics

Retrieved on: 
Tuesday, August 27, 2019
Medical tests, Ortho Clinical Diagnostics, Medicine, Ortho, Medical laboratory, In vitro, Health

RARITAN, N.J., Aug. 27, 2019 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that its board of directors has appointed Chris Smith as Chief Executive Officer effective September 9, 2019.

Key Points: 
  • RARITAN, N.J., Aug. 27, 2019 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that its board of directors has appointed Chris Smith as Chief Executive Officer effective September 9, 2019.
  • Stephen Wise, Managing Director and Global Head of Healthcare for The Carlyle Group, which invested in Ortho Clinical Diagnostics in 2014, said, "We are thrilled to welcome Chris as Ortho's next CEO.
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the global clinical laboratory and immunohematology communities.
  • This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward.

A Leap Forward in Kidney Disease Research: Scientists at Children’s Hospital Los Angeles Develop Breakthrough In Vitro Model

Retrieved on: 
Tuesday, August 13, 2019
Biotechnology, Health, Family, Consumer, Other Health, Research, Children, Hospitals, Genetics, Science, Alternatives to animal testing, In vitro, Children's Hospital Los Angeles, Los Angeles, Natural sciences

Development of new treatments requires an understanding of the mechanisms of the disease progression, but scientists have not been able to accurately model kidney filtration in vitro until now.

Key Points: 
  • Development of new treatments requires an understanding of the mechanisms of the disease progression, but scientists have not been able to accurately model kidney filtration in vitro until now.
  • View the full release here: https://www.businesswire.com/news/home/20190813005440/en/
    In a landmark study published in Nature Communications , scientists at Childrens Hospital Los Angeles demonstrate an in vitro kidney model that could change the course of research for diseases like CKD.
  • This model represents a substantial leap forward from the current standard of in vitro kidney research.
  • The Saban Research Institute of Childrens Hospital Los Angeles encompasses basic, translational and clinical research conducted at CHLA.

Ortho Achieves Distinguished No. 1 Ranking for Service in Diagnostics Industry

Retrieved on: 
Tuesday, August 6, 2019
Medical tests, Ortho Clinical Diagnostics, Medicine, Medical laboratory, Ortho, In vitro, Science, Health

RARITAN, N.J., Aug. 6, 2019 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that, for the fourth consecutive year, its Ortho Care service and support program was ranked No.

Key Points: 
  • RARITAN, N.J., Aug. 6, 2019 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that, for the fourth consecutive year, its Ortho Care service and support program was ranked No.
  • 1 for Overall Service Performance, Overall System Performance and Overall Customer Satisfaction in all three ServiceTrak industry reports: Integrated Systems, Immunoassay Analyzers and Chemistry Analyzers.
  • The Ortho Knowledge Center and robust training programs give customers education on the latest best practices and research in diagnostics.
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities.

The Europe early toxicity testing market accounted for $265 million in 2017, and is expected to reach $460 million by 2025, registering a CAGR of 7.1% from 2018 to 2025

Retrieved on: 
Tuesday, July 30, 2019
Toxicology, Health, Occupational safety and health, Environmental science, Toxicity, Toxicology testing, In vitro, OECD Guidelines for the Testing of Chemicals

Moreover, companies perform early toxicity testing to comply with the government standards to market the drug.

Key Points: 
  • Moreover, companies perform early toxicity testing to comply with the government standards to market the drug.
  • In addition, technological advancements in vitro techniques, rise in adoption of in vitro models in the Europe early toxicity testing industry and surge in adoption of early toxicity testing further boost the market growth.
  • The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints.
  • The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints.